Summary:
In patients with type 2 diabetes mellitus on premixed insulin therapy, vildagliptin as an add-on treatment significantly reduced glycemic variability and improved blood glucose control compared to treatment with premixed insulin alone, though it was associated with mild gastrointestinal side effects.
| PICO | Description |
|---|---|
| Population | Patients with type 2 diabetes mellitus inadequately controlled on premixed insulin therapy. |
| Intervention | Addition of vildagliptin to premixed insulin therapy. |
| Comparison | Premixed insulin therapy alone without vildagliptin. |
| Outcome | Vildagliptin significantly improved glycemic control by reducing glycemic variability and lowering mean blood glucose levels. However, the treatment was associated with mild gastrointestinal side effects. |
Source: Kong, Deyue, et al. “The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy.” Read article here.
